These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 8779686)

  • 21. Foscarnet--an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation?
    Ordemann R; Naumann R; Geissler G; Kroschinsky F; Bornhäuser M; Schwerdtfeger R; Ehninger G
    Ann Hematol; 2000 Aug; 79(8):432-6. PubMed ID: 10985362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.
    Bacigalupo A; Boyd A; Slipper J; Curtis J; Clissold S
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1249-64. PubMed ID: 23167560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
    Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
    Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
    Matsumura T; Narimatsu H; Kami M; Yuji K; Kusumi E; Hori A; Murashige N; Tanaka Y; Masuoka K; Wake A; Miyakoshi S; Kanda Y; Taniguchi S
    Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
    Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
    Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
    Ehlert K; Groll AH; Kuehn J; Vormoor J
    Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A; de Fabritiis P; Ghisetti V; Allice T; Mirabile M; Gentile G; Locatelli F; Falda M
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
    Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
    Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical analysis of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
    Guo Z; Chen HR; Liu XD; Bian JM; He XP; Lou JX; Chen P; Yang K; Liu D; Zhang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):971-4. PubMed ID: 22931666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
    Narimatsu H; Kami M; Kato D; Matsumura T; Murashige N; Kusumi E; Yuji K; Hori A; Shibata T; Masuoka K; Wake A; Miyakoshi S; Morinaga S; Taniguchi S
    Transpl Infect Dis; 2007 Mar; 9(1):11-5. PubMed ID: 17313465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation.
    Cesaro S; Zhou X; Manzardo C; Buonfrate D; Cusinato R; Tridello G; Mengoli C; Palù G; Messina C
    J Clin Virol; 2005 Oct; 34(2):129-32. PubMed ID: 16157264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HIV)-related cytomegalovirus infections. An open-labeled pilot study.
    Peters M; Schürmann D; Bergmann F; Grünewald T; Timm H; Pohle HD; Ruf B
    Scand J Infect Dis; 1994; 26(1):49-54. PubMed ID: 8191240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.